Shanghai Haohai Biological Technology Co., Ltd. (“Haohai Biotec”) has filed a Next Day Disclosure Return with the Hong Kong Stock Exchange detailing its latest H-share repurchase activity and current share capital position.

On 27 August 2026 the company bought back 15,000 H shares on the Exchange at prices ranging between HK$16.46 and HK$16.58 per share, for a total consideration of approximately HK$0.25 million.

Including this transaction, Haohai Biotec has repurchased 510,600 H shares since 20 July 2026 under the buy-back mandate approved on 29 May 2026. The cumulative amount equals 1.47 % of the company’s issued H-share capital outstanding on the mandate date. All repurchased shares—161,000 (20 July), 73,000 (21 July), 249,600 (24 August), 12,000 (25 August) and 15,000 (27 August)—remain pending cancellation.

Capital structure after the latest transaction: • H shares in issue (excluding treasury shares): 34.78 million • A shares in issue (excluding treasury shares): 190.20 million • A shares held as treasury shares: 3.85 million • Total issued shares: 224.98 million

The buy-back ceiling authorised by shareholders allows for up to 3.48 million H shares to be repurchased. Following the purchases to date, 2.97 million H shares remain available under the current mandate. Pursuant to listing rules, Haohai Biotec is subject to a moratorium on issuing new shares or disposing of treasury shares until 26 September 2026.

The board confirms that all repurchases complied with Hong Kong Listing Rules and other applicable regulations, and that funds due for the transactions have been fully settled.